Enlivex (ENLV) Price & Analysis

Compare

491 Followers

ENLV Stock Chart & Stats

$0.83

-$0.07(-5.60%)

At close: Jan 08 4:00 PM EST

$0.83

-$0.07(-5.60%)

Day’s Range― - ―

52-Week Range$0.79 - $2.10

Previous CloseN/A

Volume59.48K

Average Volume (3M)182.02K

Market Cap

$20.28M

Enterprise Value$2.89M

Total Cash (Recent Filing)$18.32M

Total Debt (Recent Filing)$701.00K

Price to Earnings (P/E)―

Beta0.90

Next Earnings

May 23, 2025

EPS Estimate

-0.15

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.72

Shares Outstanding24,292,833

10 Day Avg. Volume216,695

30 Day Avg. Volume182,016

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)1.02

Price to Sales (P/S)0.00

P/FCF Ratio-1.83

Enterprise Value/Market Cap0.14

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-9.90

Enterprise Value/Ebitda-0.21

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsPositive three-month top-line data from the Phase 2a stage of a multi-center, two-stage Phase 1/2 double-blind, randomized, placebo-controlled clinical trial evaluating Allocetra™ in patients with moderate-to-severe knee OA were recently reported.

Development And PartnershipsEnlivex is advancing Allocetra toward late-stage development with a planned roadmap of catalysts, including potential regulatory approval and dosing of the first patient in Phase 2b trial.

Intellectual PropertyEnlivex recently announced the issuance of an Israeli patent entitled 'Therapeutic Apoptotic Cells for Treatment of Osteoarthritis', providing added intellectual property protection in Israel through at least 2040.

Bears Say

Enlivex News

Enlivex Therapeutics files to sell 212M ordinary shares for holders

16:39 EST Enlivex Therapeutics (ENLV) files to sell 212M ordinary shares for holders Published first on TheFly –...

2h ago

ENLV

Enlivex Therapeutics closes $212M private placement

Enlivex Therapeutics (ENLV) announced the closing of the Company’s previously announced $212,000,000 private investment. Enlivex intends to use...

27d ago

ENLV

3 Penny Stocks to Watch Now, 11/25/25

Antelope Enterprise Holdings, Enlivex Therapeutics, and Inno Holdings are the 3 Penny Stocks to watch on November 25, 2025, based...

28d ago

AEHL

ENLV

Crypto Currents: Upbit plans IPO, Revolut hits $75B valuation

South Korean exchange Upbit is eyeing a U.S. listing, while JPMorgan sees major upside for bitcoin miners pivoting...

29d ago

Enlivex Therapeutics downgraded to Hold from Buy at D. Boral Capital

D. Boral Capital downgraded Enlivex Therapeutics (ENLV) to Hold from Buy with no price target after the company...

29d ago

ENLV

Enlivex Therapeutics prices 212M shares at $1.00 in private placement

Enlivex Therapeutics (ENLV) entered into a securities purchase agreement for a private investment in public equity for the...

29d ago

ENLV

Enlivex Therapeutics announces topline data from Phase I/II trial of Allocetra

Enlivex Therapeutics (ENLV) announced six-month efficacy data from the Phase IIa stage of its randomized, multi-country Phase I/II...

29d ago

ENLV

Enlivex Calls February 2026 Extraordinary Meeting to Approve Governance Changes and Reverse Share Split

An announcement from Enlivex ( ($ENLV) ) is now available. On December 18, 2025, Enlivex Therapeutics announced it...

5d ago

ENLV

Enlivex Announces Fireside Chat on RAIN Token and Allocetra Development

Enlivex ( ($ENLV) ) has issued an announcement. On December 4, 2025, Enlivex Therapeutics announced a virtual fireside...

19d ago

ENLV

Enlivex Completes $212 Million Private Placement, Expands Digital Asset Strategy

Enlivex ( ($ENLV) ) just unveiled an announcement. On November 24, 2025, Enlivex Therapeutics Ltd. completed a $212...

27d ago

ENLV

Enlivex Reports Positive Six-Month Data for Knee Osteoarthritis Trial

The latest announcement is out from Enlivex ( ($ENLV) ). Enlivex Therapeutics Ltd. announced positive six-month topline data...

29d ago

ENLV

Enlivex Completes Private Placement to Fund Digital Asset Strategy

The latest announcement is out from Enlivex ( ($ENLV) ). On November 24, 2025, Enlivex Therapeutics Ltd. announced...

29d ago

ENLV

Enlivex Reports Q3 2025 Financial Results Amidst Operational Challenges

An update from Enlivex ( ($ENLV) ) is now available. Enlivex Therapeutics Ltd. released its unaudited condensed consolidated...

1M ago

ENLV

Enlivex Reschedules Annual Meeting Due to Lack of Quorum

An update from Enlivex ( ($ENLV) ) is now available. On November 10, 2025, Enlivex Therapeutics Ltd. attempted...

1M ago

ENLV

ENLV FAQ

What was Enlivex Therapeutics Ltd’s price range in the past 12 months?

Enlivex Therapeutics Ltd lowest stock price was $0.79 and its highest was $2.10 in the past 12 months.

What is Enlivex Therapeutics Ltd’s market cap?

Enlivex Therapeutics Ltd’s market cap is $20.28M.

When is Enlivex Therapeutics Ltd’s upcoming earnings report date?

Enlivex Therapeutics Ltd’s upcoming earnings report date is May 23, 2025 which is 214 days ago.

How were Enlivex Therapeutics Ltd’s earnings last quarter?

Enlivex Therapeutics Ltd released its earnings results on May 24, 2024. The company reported -$0.25 earnings per share for the quarter, the consensus estimate of -$0.25 by $0.

Is Enlivex Therapeutics Ltd overvalued?

According to Wall Street analysts Enlivex Therapeutics Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Enlivex Therapeutics Ltd pay dividends?

Enlivex Therapeutics Ltd does not currently pay dividends.

What is Enlivex Therapeutics Ltd’s EPS estimate?

Enlivex Therapeutics Ltd’s EPS estimate is -0.15.

How many shares outstanding does Enlivex Therapeutics Ltd have?

Enlivex Therapeutics Ltd has 24,292,833 shares outstanding.

What happened to Enlivex Therapeutics Ltd’s price movement after its last earnings report?

Enlivex Therapeutics Ltd reported an EPS of -$0.25 in its last earnings report, expectations of -$0.25. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Enlivex Therapeutics Ltd?

Currently, no hedge funds are holding shares in ENLV

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Enlivex Therapeutics Ltd

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.

Enlivex (ENLV) Earnings & Revenues

Historic Earnings Reports

ENLV Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","-1":"-$1","0.5":"$0.5","3.5":"$3.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.5,2,3.5,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.05,0.9692307692307692,0.8884615384615385,0.8076923076923077,0.726923076923077,0.6461538461538462,0.5653846153846154,0.48461538461538467,0.40384615384615385,0.32307692307692304,0.24230769230769234,0.16153846153846152,0.0807692307692307,{"y":null,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.05,0.9692307692307692,0.8884615384615385,0.8076923076923077,0.726923076923077,0.6461538461538462,0.5653846153846154,0.48461538461538467,0.40384615384615385,0.32307692307692304,0.24230769230769234,0.16153846153846152,0.0807692307692307,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.05,0.9692307692307692,0.8884615384615385,0.8076923076923077,0.726923076923077,0.6461538461538462,0.5653846153846154,0.48461538461538467,0.40384615384615385,0.32307692307692304,0.24230769230769234,0.16153846153846152,0.0807692307692307,{"y":null,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.8,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.75,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.36,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.3,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.36,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.17,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.2,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.95,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >